http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Young Kul Jung ),( Dong-won Lee ),( Ja Seol Koo ),( Jung Wan Choe ),( Sang Jun Suh ),( Seung Young Kim ),( Jong Jin Hyun ),( Sung Woo Jung ),( Hyung Joon Yim ),( Sang Woo Lee ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Hepatitis delta virus (HDV) and hepatitis B virus (HBV) coinfection is associated with more severe liver disease than HBV alone. More knowledge on the epidemiology and clinical impact of HDV-infected individuals is needed in Korea. Despite the development of new antiviral agents of HDV these days, it is not well known characteristics and prevelance of hepatitis delta virus infection in patients with chronic hepatitis B in Korea. Methods: Total 1263 HBV infected patients visiting liver clinic at Korea University Ansan Hospital from January to December 2014 were screened for anti-HDV antibodies using ELISA assays. Comfirmed positive samples were further tested for HDV RNA using a commercial RT-PCR assay. Clinical characteristics and biological data from patients were researched and compared based on anti-HDV antibodies and HCV RNA results Results: Most patients (n=814, 65%) were men and mean age was 49 years old. Anti-HDV anti-bodies were detected in 11 individuals (0.87%), 2 of whom were HDV RNA positive. Anti-HDV antibody positive patients showed similar clinical features, these had liver cirrhosis (45.5% vs. 33.8%, P=0.524) and HCC (18.2% vs. 12.9%, P=0.643) compared with HDV negative. However, all of 2 patients with HDV-RNA positivity showed significant cirrhosis. Conclusions: HDV infection is rare in patients with chronic hepatitis B in Korea, but is related with liver cirrhosis in HDV RNA positive patients. However, HDV co-infection may not have a clinical importance.
사례보고 : 원발성 간세포암종의 늑골전이를 경동맥화학색전술로 치료한 1예
정영걸 ( Young Kul Jung ),연종은 ( Jong Eun Yeon ),김청호 ( Chung Ho Kim ),이현정 ( Hyun Jung Lee ),이영선 ( Young Sun Lee ),윤아일린 ( Eileen L. Yoon ),정은석 ( Eun Suck Jung ),최종환 ( Jong Hwan Choi ),김지훈 ( Ji Hoon Kim ),변 대한간학회 2009 Clinical and Molecular Hepatology(대한간학회지) Vol.15 No.3
뼈는 간세포암종의 전이 장소 중 세 번째로 흔하게 발생하는 곳으로 이에 대한 치료는 제한적이다. 55세 남자 환자가 우하흉부 통증으로 내원하여 원발성 간세포암종과 우측 8번 늑골전이로 진단되었다. 혈관조영술에서 우측 8번 늑간동맥으로부터 공급되는 늑골의 종양이 관찰되어 총 3회의 경동맥 화학색전술을 시행하였고, 이후 두 차례의 컴퓨터 단층촬영에서는 우측 8번 늑골 종양 부위에 치밀한 리피오돌 침착이 관찰되었으며, 통증은 소실되었다. 이에 저자들은 경동맥화학색전술로 치료한 원발성 간세포암종 환자의 늑골전이 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Bone is a common site of metastasis in patients with hepatocellular carcinoma (HCC). We report a rare case of rib metastasis from HCC treated by transcatheter arterial chemoembolization (TACE). A 55-year-old man with liver cirrhosis presented with right lower chest pain. The diagnosis was an HCC with a bone metastasis in the right eighth rib. Intra-arterial injections of doxorubicin mixed with Lipiodol and Gelfoam particles were instituted through the right eighth intercostal artery. Computed tomography and a Tc99-labeled scan performed 2 months after the third TACE revealed no viable HCC in the right eighth rib. (Korean J Hepatol 2009;15:357-361)
Jung, Young Kul,Kim, Ji Hoon,Ahn, Sung-Min,Yang, Jae Won,Park, Sang Jin,Kim, Jong Woo,Yeon, Jong Eun,Kwon, Oh Sang,Kim, Yun Soo,Choi, Duck Joo,Kim, Ju Hyun,Byun, Kwan Soo by Lippincott WilliamsWilkins 2013 Journal of clinical gastroenterology Vol.47 No.7
BACKGROUND:: Genetic variations in interleukin 28B (IL28B) have been strongly associated with a sustained virological response (SVR) in European and African-American patients. Genetic variation of IL28B was investigated in healthy controls and chronic hepatitis C (CHC) patients, and the treatment response in the CHC patients was analyzed according to IL28B polymorphism in the Korean population. METHODS:: IL28B polymorphisms (rs12979860 and rs8099917) were studied in 200 healthy controls and in 167 CHC patients who were treated with peginterferon-α and ribavirin. RESULTS:: The prevalence of rs12979860 in healthy controls is as follows: the CC-genotype was 88.5%, the CT-genotype was 11.5%, and the TT-genotype was not found. The prevalence of rs8099917 in healthy controls is as follows: the TT-genotype was 89.5%, the TG-genotype was 10.5%, and the GG-genotype was not found. The CC-genotype of rs12979860 and the TT-genotype of rs8099917 were found to be closely related (linkage disequilibrium; D&vprime;=1.0, &khgr; =0.9082). In 106 CHC patients treated with peginterferon and ribavirin, the SVR was 67.2% (n=58) for 1b, 91.6% (n=47) for 2a. In hepatitis C virus (HCV) genotype 1b with respect to rs12979860, the SVR in CC-genotype was 72.9% and that in CT-genotype was 40.0%. On investigating predictive factors for SVR, pretreatment low-HCV RNA levels, HCV genotype non-1, early virological response, and also the IL28B CC-genotype for rs12979860 were good indicators of an SVR. CONCLUSIONS:: In Korea, genetic variation of IL28B is different from that in western countries in view of high prevalence of rs12979860 CC-genotype. It seems likely that a high SVR in Korean patients with genotype 1 CHC patients is due to the genetic polymorphism in IL28B.
( Young Eun Ahn ),( Sang Jun Suh ),( Hyung Joon Yim ),( Yeon Seok Seo ),( Eileen L. Yoon ),( Tae Hyung Kim ),( Young Sun Lee ),( Sun Young Yim ),( Hae Rim Kim ),( Seong Hee Kang ),( Young Kul Jung ),( 대한소화기학회 2021 Gut and Liver Vol.15 No.2
Background/Aims: Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced HCC with main portal vein tumor thrombosis (PVTT). This study aimed to compare the efficacy of sorafenib-based therapy with that of HAIC-based therapy for advanced HCC with main PVTT. Methods: Advanced HCC patients with main PVTT treated with sorafenib or HAIC between 2008 and 2016 at Korea University Medical Center were included. We evaluated overall survival (OS), time-to-progression (TTP), and the disease control rate (DCR). Results: Seventy-three patients were treated with sorafenib (n=35) or HAIC (n=38). Baseline characteristics were not significantly different between groups, except the presence of solid organ metastasis (46% vs 5.3%, p<0.001). The median OS time was not significantly different between the groups (6.4 months vs 10.0 months, p=0.139). TTP was longer in the HAIC group than in the sorafenib group (2.1 months vs 6.2 months, p=0.006). The DCR was also better in the HAIC group than in the sorafenib group (37% vs 76%, p=0.001). Subgroup analysis, which excluded patients with extrahepatic solid organ metastasis, showed the same trends for the median OS time (8.8 months vs 11.1 months, p=0.097), TTP (1.9 months vs 6.0 months, p<0.001), and DCR (53% vs 81%, p=0.030). Conclusions: HAIC-based therapy may be an alternative to sorafenib for advanced HCC with main PVTT by providing longer TTP and a better DCR. (Gut Liver 2021;15:284-294)
( Jung Hyun Kwon ),( Young Seok Kim ),( Sang Gyune Kim ),( Jeong Won Jang ),( Tae Hun Kim ),( Young Kul Jung ),( Oh Sang Kwon ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Genotype C is the principal type of hepatitis B virus in Koreans and is associated with poor prognosis for Peginterferon (PEF-IFN) α-2a therapy. The Korea Health Insurance supports only 24 weeks of therapy in HBeAg positive patients, and there is little report of PEG-IFN α-2a therapy in Korea. Authors investigated the efficacy and compliance to PEG-IFN α-2a therapy in Koreans with chronic hepatitis B (CHB) in a real clinical setting. Methods: CHB patients treated with PEG-IFN α-2a from 2008 to 2011 at four tertiary university hospitals were retrospectively enrolled. Laboratory analyses and adverse events were investigated. Treatment outcomes were evaluated at the end of treatment and at 24 weeks after treatment completion. Results: Eighty-eight patients were enrolled; 67 were HBeAg positive and 50 were men. The mean treatment period was 35.1±8.8 weeks. In 27.3% of the patients, treatment was discontinued due to insufficient antiviral effects (10.2%) and adverse events (9.1%). When patients that completed therapy were analyzed 24 weeks after treatment, 31% of HBeAg positive patients achieved HBV DNA suppression to < 104 c/ml (SVR) and 24.1% of patients achieved HBeAg seroconversion. In HBeAg negative patients, 75% of patients achieved SVR, and 86.7% of patients maintained SVR. By multivariate analysis, a week 24 viral load > 5 log copies/ml was only sig- nificant factor for SVR. During the follow-up period (76.1±46.5 weeks), 29.8% of patients developed a breakthrough HBV DNA level of > 107 c/ml after a reduction to < 104 c/ml and 29.4% of patients reversed HBeAg. No deaths or admissions were attributed to adverse events. Conclusions: These results suggest that PEG-IFN α-2a therapy in Koreans with CHB, showed acceptable virologic response and durability. However, the rate of premature discontinuation was higher in real clinical setting of the present study than in previously reported controlled trials.
( Young Kul Jung ),( Sang Jun Suh ),( Hyung Joon Yim ),( Oh Sang Kwon ),( Yun Soo Kim ),( Duck Joo Choi ),( Ju Hyun Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Current treatment guidelines recommend either entecavir (ETV) or tenofovir (TDF) as first line treatment for management of chronic hepatitis B patients given their high antiviral potency, favorable tolerability profile, and high genetic barriers to the development of antiviral resistance. However, it is not clear whether the efficacy reported from head-to-head trial is similar to the outcomes seen in routine practice. So, our aim is to investigate the treatment outcomes of antiviral therapy in a clinical practice. Methods: We conducted a prospective cohort study of 130 treatment- naive patients who started either ETV or TDF by randomization manner between Januanry 2013 and December 2014. Primary endpoint was complete viral suppression rate (HBV DNA real-time PCR < 20 IU/mL) at 12 month after treatment (ClinicalTrials.gov Identifier: NCT01776814). Results: Total 130 CHB patients were enrolled and randomized in both group. However, 15 patients were dropped by any lesion and 104 patients (80%) were remain at 12 months. The majority of patients in both ETV and TDF group were male (73%), HBeAg negative (60%), and non-cirrhotic patients (52%). Pretreatment serum ALT, HBV DNA level, bilirubin, and albumin level were similar between two groups (p=n.s.). At treatment 12 months, both group achieved similar complete virological response: 85% vs. 86%, respectively (p=0.26). Biochemical response is also similar: 95% vs. 96%, respectively (p=0.3). Among HBeAg positive patients, 6 patients showed HBeAg loss ( 2 patients in ETV, 4 in TDF) and 2 patients achieved HBeAg seroconversion (1 at ETV, 1 at TDF). 3 patients experienced side effect and stopped medication (1 at ETV, 2 at TDF). However, there was no serious side effect during treatment period. Conclusions: Treatment-naive CHB patients treated with either ETV or TDF achieved a similar rate of complete virological and biochemical response at 12 months. However, drop rate was slightly high regardless of drug and attention to medication adherence is needed in a clinical practice.
( Jung Wan Choe ),( Hyung Joon Yim ),( Seung Hwa Lee ),( Hwan Hoon Chung ),( Sang Jun Suh ),( Seung Young Kim ),( Jong Jin Hyun ),( Sung Woo Jung ),( Young Kul Jung ),( Ja Seol Koo ),( Ji Hoon Kim ),( 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: No single effective method has yet been established for the prophylactic treatment of gastric varices. So, we aimed to compare two prophylactic treatment methods, including EVO and BRTO for gastric varices. Methods: We retrospectively analyzed patients with gastric varices, who had undergone either EVO or BRTO as a prophylactic treatment. The end points were eradication rate of gastric varices and gastric variceal bleeding rate during the follow-up period. Results: Total 84 patients were consisted of 55 patients in EVO group and 29 patients in BRTO group. No difference was observed in the clinical profiles of patients, including age, gender, Child-Pugh score, etiology of liver cirrhosis, and presence of hepatocellular carcinoma, between the EVO and BRTO groups. There was also no difference with respect to endoscopic features of gastric varices including F-component and location. As primary end points, the gastric varices were disappeared partially or completely in 50 patients in EVO group, and 27 patients in BRTO group. (90.9% vs 93.1%, p= 0.542). At the complete eradication rate, there was also no difference between two groups. (49.1% vs 65.5%, p=-0.150) However, 12 patients in EVO group bled from gastric varices after treatment during the median follow-up of 28 months, compared to only one case in BRTO group. (21.8% vs 3.4%, p=0.027) In addition, there were no differences in worsening in the endoscopic classification of esophageal varices or amounts of ascites. All-cause mortalities were similar in both. Conclusions: EVO and BRTO are equally effective for eradication of gastric varices with similar frequencies of complications and mortalities. However, BRTO proved more effective in preventing bleeding from gastric varices in the long run.